113 related articles for article (PubMed ID: 21793567)
1. Fully activated MEK1 exhibits compromised affinity for binding of allosteric inhibitors U0126 and PD0325901.
Sheth PR; Liu Y; Hesson T; Zhao J; Vilenchik L; Liu YH; Mayhood TW; Le HV
Biochemistry; 2011 Sep; 50(37):7964-76. PubMed ID: 21793567
[TBL] [Abstract][Full Text] [Related]
2. Thermodynamics of nucleotide and non-ATP-competitive inhibitor binding to MEK1 by circular dichroism and isothermal titration calorimetry.
Smith CK; Windsor WT
Biochemistry; 2007 Feb; 46(5):1358-67. PubMed ID: 17260965
[TBL] [Abstract][Full Text] [Related]
3. Identification and characterization of a novel chemotype MEK inhibitor able to alter the phosphorylation state of MEK1/2.
Yoshida T; Kakegawa J; Yamaguchi T; Hantani Y; Okajima N; Sakai T; Watanabe Y; Nakamura M
Oncotarget; 2012 Dec; 3(12):1533-45. PubMed ID: 23237773
[TBL] [Abstract][Full Text] [Related]
4. The transcription factor GATA4 is activated by extracellular signal-regulated kinase 1- and 2-mediated phosphorylation of serine 105 in cardiomyocytes.
Liang Q; Wiese RJ; Bueno OF; Dai YS; Markham BE; Molkentin JD
Mol Cell Biol; 2001 Nov; 21(21):7460-9. PubMed ID: 11585926
[TBL] [Abstract][Full Text] [Related]
5. Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors.
Henderson YC; Fredrick MJ; Clayman GL
Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):810-5. PubMed ID: 17709622
[TBL] [Abstract][Full Text] [Related]
6. Off-target effects of MEK inhibitors.
Wauson EM; Guerra ML; Barylko B; Albanesi JP; Cobb MH
Biochemistry; 2013 Aug; 52(31):5164-6. PubMed ID: 23848362
[TBL] [Abstract][Full Text] [Related]
7. Enzyme kinetics and binding studies on inhibitors of MEK protein kinase.
VanScyoc WS; Holdgate GA; Sullivan JE; Ward WH
Biochemistry; 2008 Apr; 47(17):5017-27. PubMed ID: 18393446
[TBL] [Abstract][Full Text] [Related]
8. U0126, a mitogen-activated protein kinase kinase 1 and 2 (MEK1 and 2) inhibitor, selectively up-regulates main isoforms of CYP3A subfamily via a pregnane X receptor (PXR) in HepG2 cells.
Smutny T; Bitman M; Urban M; Dubecka M; Vrzal R; Dvorak Z; Pavek P
Arch Toxicol; 2014 Dec; 88(12):2243-59. PubMed ID: 24819614
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17.
Kiga M; Tanzawa F; Iwasaki S; Inaba F; Fujiwara K; Iwadare H; Echigo T; Nakamura Y; Shibata T; Suzuki K; Yasumatsu I; Nakayama A; Sasazawa Y; Tashiro E; Imoto M; Kurakata S
Anticancer Drugs; 2012 Jan; 23(1):119-30. PubMed ID: 22008853
[TBL] [Abstract][Full Text] [Related]
10. Moxibustion eases chronic inflammatory visceral pain through regulating MEK, ERK and CREB in rats.
Li ZY; Huang Y; Yang YT; Zhang D; Zhao Y; Hong J; Liu J; Wu LJ; Zhang CH; Wu HG; Zhang J; Ma XP
World J Gastroenterol; 2017 Sep; 23(34):6220-6230. PubMed ID: 28974888
[TBL] [Abstract][Full Text] [Related]
11. Aggravation of necrotic death of glucose-deprived cells by the MEK1 inhibitors U0126 and PD184161 through depletion of ATP.
Yung HW; Wyttenbach A; Tolkovsky AM
Biochem Pharmacol; 2004 Jul; 68(2):351-60. PubMed ID: 15194007
[TBL] [Abstract][Full Text] [Related]
12. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors.
Thottassery JV; Sun Y; Westbrook L; Rentz SS; Manuvakhova M; Qu Z; Samuel S; Upshaw R; Cunningham A; Kern FG
Cancer Res; 2004 Jul; 64(13):4637-47. PubMed ID: 15231676
[TBL] [Abstract][Full Text] [Related]
13. ERK1/2-driven and MKP-mediated inhibition of EGF-induced ERK5 signaling in human proximal tubular cells.
Sarközi R; Miller B; Pollack V; Feifel E; Mayer G; Sorokin A; Schramek H
J Cell Physiol; 2007 Apr; 211(1):88-100. PubMed ID: 17131384
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Bifunctional Oncogenic Target Inhibitors against Allosteric Mitogen-Activated Protein Kinase (MEK1) and Phosphatidylinositol 3-Kinase (PI3K).
Van Dort ME; Hong H; Wang H; Nino CA; Lombardi RL; Blanks AE; Galbán S; Ross BD
J Med Chem; 2016 Mar; 59(6):2512-22. PubMed ID: 26943489
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of triple negative breast cancer cells with combination of mTOR1/2 inhibitor AZD8055 and MEK1/2 inhibitor PD0325901].
Nan XY; Wu Y; Zhang LH; Yang ZJ
Yao Xue Xue Bao; 2016 Oct; 51(10):1551-7. PubMed ID: 29932599
[TBL] [Abstract][Full Text] [Related]
16. Positive regulation of Raf1-MEK1/2-ERK1/2 signaling by protein serine/threonine phosphatase 2A holoenzymes.
Adams DG; Coffee RL; Zhang H; Pelech S; Strack S; Wadzinski BE
J Biol Chem; 2005 Dec; 280(52):42644-54. PubMed ID: 16239230
[TBL] [Abstract][Full Text] [Related]
17. Computational Models for Activated Human MEK1: Identification of Key Active Site Residues and Interactions.
Sabsay KR; Lee RT; Ravatt LM; Oza JP; McDonald AR
J Chem Inf Model; 2019 May; 59(5):2383-2393. PubMed ID: 30879307
[TBL] [Abstract][Full Text] [Related]
18. MEK/Erk-based negative feedback mechanism involved in control of Steel Factor-triggered production of Krüppel-like factor 2 in mast cells.
Marschall JS; Wilhelm T; Schuh W; Huber M
Cell Signal; 2012 Apr; 24(4):879-88. PubMed ID: 22182511
[TBL] [Abstract][Full Text] [Related]
19. Picroside II Inhibits the MEK-ERK1/2-COX2 Signal Pathway to Prevent Cerebral Ischemic Injury in Rats.
Wang T; Zhai L; Zhang H; Zhao L; Guo Y
J Mol Neurosci; 2015 Nov; 57(3):335-51. PubMed ID: 26240040
[TBL] [Abstract][Full Text] [Related]
20. Mitogen-activated protein kinases p38 and ERK 1/2 mediate the wall stress-induced activation of GATA-4 binding in adult heart.
Tenhunen O; Sármán B; Kerkelä R; Szokodi I; Papp L; Tóth M; Ruskoaho H
J Biol Chem; 2004 Jun; 279(23):24852-60. PubMed ID: 15051723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
